|Bid||1.17 x 4400|
|Ask||1.21 x 2500|
|Day's Range||1.16 - 1.22|
|52 Week Range||1.13 - 6.79|
|PE Ratio (TTM)||-1.07|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Q2 2017 Merrimack Pharmaceuticals Inc Earnings Call
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.
The Cambridge, Massachusetts-based company said it had profit of $3.86 per share. Losses, adjusted to account for discontinued operations, were 22 cents per share. The results did not meet Wall Street ...